Qualitative Interviews to Better Understand the Patient Experience and Evaluate Patient-Reported Outcomes (PRO) in RLBP1 Retinitis Pigmentosa (RLBP1 RP)

被引:12
|
作者
Green, Jane [1 ]
Tolley, Chloe [2 ]
Bentley, Sarah [2 ]
Arbuckle, Rob [2 ]
Burstedt, Marie [3 ]
Whelan, James [1 ]
Holopigian, Karen [4 ]
Stasi, Kali [5 ]
Sloesen, Brigitte [6 ]
Spera, Claudio [7 ]
Deslandes, Jean-Yves [7 ]
Mullins, Anmol [7 ]
机构
[1] Mem Univ Newfoundland, St John, NF, Canada
[2] Adelphi Values, Bollington, England
[3] Univ Umea, Umea, Sweden
[4] Novartis Inst Biomed Res, E Hanover, NJ USA
[5] Novartis Inst Biomed Res, Cambridge, MA USA
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Novartis Pharma AG, Basel, Switzerland
关键词
Interview; Qualitative; Quality of life; RLBP1 retinitis pigmentosa; RLBP1; RP; Visual functioning; RETINALDEHYDE-BINDING PROTEIN; OF-LIFE; PUNCTATA ALBESCENS; FUNDUS-ALBIPUNCTATUS; DATA SATURATION; GENE RLBP1; BOTHNIA DYSTROPHY; LOW LUMINANCE; MUTATIONS; QUESTIONNAIRE;
D O I
10.1007/s12325-020-01275-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction RLBP1 RP is an autosomal recessive form of retinitis pigmentosa (RP), characterized by night blindness, prolonged dark adaptation, constricted visual fields and impaired macular function. This study aimed to better understand the patient experience of RLBP1 RP and evaluate the content validity of existing patient reported outcome (PRO) instruments in this condition. Methods Semi-structured concept elicitation and cognitive debriefing interviews were conducted with RLBP1 RP patients in Canada and Sweden. Interviews started with open-ended concept elicitation questioning, and then patients were cognitively debriefed on The National Eye Institute Visual Functioning Questionnaire (NEI VFQ-25), the Low Luminance Questionnaire (LLQ) and four light/dark adaptation items of the Visual Activities Questionnaire (VAQ). Qualitative interviews were also conducted with three expert clinicians. Anonymized, verbatim transcripts were analyzed using thematic analysis. Results Twenty-one patients were interviewed (Canada n = 10; Sweden n = 11). Symptoms reported included night blindness (n = 21), difficulty adapting to changes in lighting (n = 21) and difficulties seeing in bright lighting (n = 18). Patients experienced substantial impacts on daily activities (n = 21) and physical functioning (n = 17). Patients had difficulty interpreting and selecting a response for some items in the NEI VFQ-25 and LLQ. Some items were not relevant to patients' disease experience. There were both gaps and overlaps in the conceptual coverage of the instruments. Conclusions Visual impairment due to RLBP1 RP has a substantial impact on physical functioning and daily activities. To adequately assess all important symptoms and associated functional impacts in RLBP1 RP, it is recommended to either modify one or more existing instruments or to develop a new non-syndromic RP specific instrument.
引用
收藏
页码:2884 / 2901
页数:18
相关论文
共 49 条
  • [41] Preliminary results of a German non-interventional study over 12 months to evaluate the relationships between physical activity and course of disease and patient-reported outcomes in multiple sclerosis patients treated with interferon β-1b
    Koehler, J.
    Fischer, J.
    Boehringer, J.
    Schieb, H.
    Seibert, S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 712 - 713
  • [42] Longitudinal patient-reported outcomes (PROs) and qualitative assessment of symptom burden within a phase 1b trial of a PARP inhibitor olaparib combined with an oral mTORC1/2 inhibitor (AZD2014) or an AKT inhibitor (AZD5363)
    Meyer, Larissa A.
    Sun, Charlotte
    Shi, Qiuling
    Westin, Shannon
    Haq, Shireen
    Savelieva, Katerina
    Coleman, Robert
    Mills, Gordon
    Williams, Loretta
    QUALITY OF LIFE RESEARCH, 2018, 27 : S77 - S77
  • [43] Patient-reported outcomes (PRO) in patients (pts) with BRCA1/2-altered metastatic castration-resistant prostate cancer (mCRPC) receiving niraparib (NIRA) with abiraterone acetate and prednisone (AAP): Results from MAGNITUDE study
    Rathkopf, Dana E.
    Roubaud, Guilhem
    Chi, Kim N.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Small, Eric J.
    Saad, Marniza
    Castro, Elena
    Kim, Won
    Wu, Daphne
    Bertzos, Kristi
    Dibaj, Shiva
    Zhang, Jenny
    Francis, Peter St. John
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 105 - 105
  • [44] Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2 (Oct, 10.1007/s11136-021-02968-1, 2021)
    Mazza, Gina L.
    Petersen, Molly M.
    Ginos, Brenda
    Langlais, Blake T.
    Heon, Narre
    Gounder, Mrinal M.
    Mahoney, Michelle R.
    Zoroufy, Alexander J.
    Schwartz, Gary K.
    Rogak, Lauren J.
    Thanarajasingam, Gita
    Basch, Ethan
    Dueck, Amylou C.
    QUALITY OF LIFE RESEARCH, 2022, 31 (04) : 1081 - 1081
  • [45] Improved treatment satisfaction with once-weekly insulin icodec compared with once-daily basal insulin in individuals with type 2 diabetes: An analysis of patient-reported outcomes and participant interviews from ONWARDS 2 and 5 and a physician survey from ONWARDS 1
    Polonsky, William
    Benamar, Malik
    Carstensen, Lisbeth
    Davies, Melanie
    Donatsky, Anders Meller
    Franek, Edward
    Kellerer, Monika
    Philis-Tsimikas, Athena
    Goldenberg, Ronald
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 217
  • [46] Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician's choice chemotherapy treatment (PCT): A focus on the EMBRACA triple negative (TNBC) subpopulation
    Rugo, H. S.
    Quek, R.
    Ettl, J.
    Hurvitz, S. A.
    Bhattacharyya, H.
    Hannah, A. L.
    Litton, J. K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] Treatment with Interferon (IFN) and Ribavirin (RBV)-Free Regimens with Ledipasvir (LDV) and Sofosbuvir (SOF) Improves Patient-Reported Outcomes (PRO) for Patients with Genotype 1 (GT1) Chronic Hepatitis C (CH-C): Results from the ION-1,2 and 3 Clinical Trials
    Younossi, Zobair
    Stepanova, Maria
    Marcellin, Patrick
    Afdhal, Nezam H.
    Kowdley, Kris V.
    Zeuzem, Stefan
    Hunt, Sharon L.
    HEPATOLOGY, 2014, 60 : 235A - 236A
  • [48] PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS (PTS) WITH HER2-ADVANCED BREAST CANCER (ABC) RECEIVING TALAZOPARIB (TALA) VS PHYSICIAN'S CHOICE CHEMOTHERAPY (PCT): A FOCUS ON EMBRACA GERMLINE BRCA1 AND BRCA2 MUTATION (GBRCA1/2M) SUBGROUPS
    Goncalves, Anthony
    Quek, Ruben G. W.
    Bhattacharyya, Helen
    Ettl, Johannes
    Hurvitz, Sara A.
    Rugo, Hope S.
    BREAST, 2019, 48 : S71 - S71
  • [49] Patient-reported outcomes (PRO) with talazoparib (TALA) vs physician's choice chemotherapy (PCT) in patients (pts) with HER2-advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm): Subgroup analysis of pts with and without TALA dose reductions vs PCT in the EMBRACA trial
    Rugo, H. S.
    Niyazov, A.
    Bhattacharyya, H.
    Arondekar, B.
    Hurvitz, S. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S480 - S480